June 28, 2020
1 min read

Chinese Vaccine Shows Positive Results In Human Trials

https://www.youtube.com/watch?v=gLGZ1v9D4xY

A Covid-19 vaccine candidate developed by a Beijing unit of China National Biotec Group (CNBG) has shown positive results in early human trials, the company said on Sunday. According to the company, all 1,120 volunteers in the phase-1 and phase-2 clinical trials produced high-titer antibodies against Covid-19 after accepting two doses of the vaccine, the Global Times reported.

The clinical trials which started on April 27 in Shangqiu county in China’s Henan province have shown the vaccine to be effective and safe, said CNBG.

The trials were designed as randomised, double-blind and placebo-controlled studies.

This is not the first Covid-19 vaccine candidate from CNBG, which is affiliated to the state-owned China National Pharmaceutical Group (Sinopharm).

First special law in China vaccine released

In the middle of this month, another institute under CNBG in Wuhan announced the results of phase-1 and Phase-2 clinical trials of an inactivated Covid-19 vaccine candidate it developed.

These trials, which started on April 12, also involved 1,120 volunteers and the results revealed a good safety record, with no cases of severe adverse effects found in the clinical trials.

CNBG on June 23 announced an agreement with authorities in the United Arab Emirates to start phase-3 clinical trials for inactivated vaccine candidates.

It is not clear which of CNBG’s Covid-19 vaccine candidates will be tested in the phase-3 trial in the UAE.

Also Read-19% Drop In China’s Industrial Profits

 

 

 

 

Previous Story

19% Drop In China’s Industrial Profits

Next Story

India-China Border Row Affects India Inc

Latest from China

China to raise tariffs on US goods to 125%

Trump’s universal tariffs on China total 145%. When Trump announced Wednesday that China faced 125% tariffs, he did not include a 20% tariff on China tied to its role in fentanyl production

Trump Targets China, Spares Allies

The latest hike in tariffs comes after China raised its tariffs on US imports from 34 per cent to 84 per cent, effective April 10, which itself was a response to an

India Tightens Checks on Chinese Imports

India has ramped up monitoring of Chinese imports amid growing concerns of cheap goods being redirected into the Indian market following the United States’ steep tariff hike on Chinese exports. Commerce Secretary
Go toTop